Nirogy Therapeutics is focusing on small-molecule drugs that target the solute carrier family of transporter proteins (SLCTs). Founded in 2013, Nirogy Therapeutics is backed by investors that include Sporos Bioventures and Sante Ventures and is headquartered in Natick.